USO 24246
A Phase II Study Investigating Fruquintinib plus FOLFIRI as Second-Line Treatment for Participants with Metastatic Colorectal Cancer (mCRC)
Disease Types: Gastrointestinal Cancer Research
Eligibility Requirements:
• Subjects must have confirmed mCRC
• Subjects with genetic aberrations are allowed
• No MSI-H and BRAF V600
• Subjects must have received FOLFOX and BEV-based first
line of therapy
• Subjects that received more than 1 treatment regimen
for mCRC are excluded
• Subjects that have received neo/adjuvant therapy and
were disease free for >6 months before recurrence are
eligible
• Subjects who received neo/adjuvant FOLFOX and
progressed within 6 months are excluded
• ECOG score ≤ 2
For more information on this trial CLICK HERE .
Available at:
- Chesapeake
- Hampton (CarePlex)
- Norfolk (Brock Cancer Center)
- Newport News (Port Warwick III)
- Suffolk (Harbour View)
- Virginia Beach (Princess Anne)
- Williamsburg